A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.

Subotheni ThavaneswaranMaya KansaraFrank LinDavid EspinozaJohn P GradyChee Khoon LeeMandy L BallingerLucille SebastianTheresa CorpuzMin Ru QiuPiyushkumar MundraCharles G BaileyUlf SchmitzJohn SimesAnthony M JoshuaDavid M Thomas

Published in: British journal of cancer (2023)

O + D demonstrated no new toxicity concerns and yielded a clinically meaningful PFS6 rate and durable OTRs across several cancers with HRR defects, including rare cancers.

Keyphrases

dna damage
dna repair
genome wide
open label
copy number
dna methylation
gene expression
young adults
transcription factor
double blind
genome wide analysis